IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 92 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (456 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References
   Article Figures

 Article Access Statistics
    Viewed31    
    Printed0    
    Emailed0    
    PDF Downloaded1    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2020  |  Volume : 52  |  Issue : 4  |  Page : 335-336
 

Human immunodeficiency virus, neuroinflammation, CD16+ pathobiological process, and haloperidol drug


1 Private Academic Consultant, Bangkok, Thailand
2 Department of Biological Science, Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria

Date of Submission21-Oct-2019
Date of Decision10-Jan-2020
Date of Acceptance18-Sep-2020
Date of Web Publication14-Oct-2020

Correspondence Address:
Dr. Beuy Joob
Private Academic Consultant, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.IJP_688_19

Rights and Permissions



How to cite this article:
Joob B, Wiwanitkit V. Human immunodeficiency virus, neuroinflammation, CD16+ pathobiological process, and haloperidol drug. Indian J Pharmacol 2020;52:335-6

How to cite this URL:
Joob B, Wiwanitkit V. Human immunodeficiency virus, neuroinflammation, CD16+ pathobiological process, and haloperidol drug. Indian J Pharmacol [serial online] 2020 [cited 2020 Oct 20];52:335-6. Available from: https://www.ijp-online.com/text.asp?2020/52/4/335/298153




Sir,

Human immunodeficiency virus (HIV) is an important agent causing retrovirus infection. This infection results in immunodeficiency problem which can further lead to many clinical problems. HIV-associated neuroinflammation is an important neurological disorder that is due to the CD16+ monocyte transmigration across the blood–brain barrier.[1] To manage HIV-associated neuroinflammation, the present new focus is usually on CD16+ monocyte. The use of a therapeutic agent that can affect the CD16+ is expected to be a useful therapeutic approach. Here, the authors would like to discuss on the possible usefulness of haloperidol, a widely used antipsychotic drug.

Regarding the effect of haloperidol, it is accepted for usefulness in the management of neuropsychiatric problems such as delirium in HIV-infected patients.[2] Recently, haloperidol is also proposed as a possible inhibitor of HIV protease.[3] Here, the authors would like to discuss on another possible additional usefulness of haloperidol regarding CD16+ biological process in HIV-infected patients. Basically, haloperidol has anti-dopamine effect. Pathophysiologically, dopamine is reported for its association with CD16+ monocyte transmigration across the blood–brain barrier and the further consequent HIV-associated neuroinflammation.[4] Applying the standard common pathway mapping bioinformatics analysis, as used in the previous study,[4] the interrelationship among HIV infection and haloperidol neuroinflammation can be identified [Figure 1]. Hence, haloperidol that has actions against dopamine can further reduce the CD16+ monocyte transmigration across the blood–brain barrier and the further consequent HIV-associated neuroinflammation. Further study on the actual pharmacological effect of haloperidol in HIV patients is a very interesting research in clinical pharmacology.
Figure 1: The interrelationship among human immunodeficiency virus infection and haloperidol neuroinflammation

Click here to view


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Mattos JP, Rosso AL, Correa RB, Novis SA. Movement disorders in 28 HIV-infected patients. Arq Neuropsiquiatr 2002;60:525-30.  Back to cited text no. 1
    
2.
Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-7.  Back to cited text no. 2
    
3.
De Voss JJ, Sui Z, DeCamp DL, Salto R, Babé LM, Craik CS, et al. Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases. J Med Chem 1994;37:665-73.  Back to cited text no. 3
    
4.
Calderon TM, Williams DW, Lopez L, Eugenin EA, Cheney L, Gaskill PJ, et al. Dopamine increases CD14 CD16 monocyte transmigration across the blood brain Barrier: implications for substance abuse and HIV neuropathogenesis. J Neuroimmune Pharmacol 2017;12:353-70.  Back to cited text no. 4
    


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow